- Home
- MCRI vs VCEL Comparison
MCRI vs VCEL Comparison
Compare MCRI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | VCEL |
|---|---|---|
| Founded | 1972 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MCRI | VCEL |
|---|---|---|
| Price | $100.14 | $32.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $100.50 | $58.50 |
| AVG Volume (30 Days) | 83.7K | ★ 446.2K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | 41.41 | ★ 60.00 |
| EPS | ★ 5.43 | 0.32 |
| Revenue | ★ $395,377,000.00 | $276,259,000.00 |
| Revenue This Year | $4.85 | $19.09 |
| Revenue Next Year | $2.21 | $17.96 |
| P/E Ratio | ★ $18.43 | $100.34 |
| Revenue Growth | ★ 114.40 | 16.45 |
| 52 Week Low | $69.99 | $29.24 |
| 52 Week High | $113.88 | $48.75 |
Technical Indicators
Market Signals| Indicator | MCRI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 34.04 |
| Support Level | $94.30 | $31.34 |
| Resistance Level | $106.87 | $38.48 |
| Average True Range (ATR) | 2.95 | 1.41 |
| MACD | 0.26 | -0.37 |
| Stochastic Oscillator | 69.01 | 15.85 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.